Miskiewicz-Migon I, Miskiewicz-Bujna J, Rosa M, Kubica-Cielinska A, Bladowska J, Janczar S, et al. Severe, reversible acute lung injury during autologous hematopoietic stem cell mobilization after filgrastim in a child with neuroblastoma: a case report. Transplant Proc. 2020;52(9):2849–53. https://doi.org/10.1016/j.transproceed.2020.06.027.

Article  PubMed  Google Scholar 

Hollingshead LM, Goa KL. Recombinant granulocyte colony-stimulating factor (rg-csf). A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs. 1991;42(2):300–30. https://doi.org/10.2165/00003495-199142020-00009.

Article  CAS  PubMed  Google Scholar 

Caselli D, Cesaro S, Arico M. Biosimilars in the management of neutropenia: focus on filgrastim. Biologics. 2016;10:17–22. https://doi.org/10.2147/BTT.S73580.

Article  PubMed  PubMed Central  Google Scholar 

Arimura K, Inoue H, Kukita T, Matsushita K, Akimot M, Kawamata N, et al. Acute lung injury in a healthy donor during mobilization of peripheral blood stem cells using granulocyte-colony stimulating factor alone. Haematologica. 2005;90(3):R10.

Google Scholar 

Yamamoto K, Doki N, Senoo Y, Najima Y, Kobayashi T, Kakihana K, et al. Severe hypoxemia in a healthy donor for allogeneic hematopoietic stem cell transplantation after only the first administration of granulocyte-colony stimulating factor. Transfus Med Hemother. 2016;43(6):433–5. https://doi.org/10.1159/000446814.

Article  PubMed  PubMed Central  Google Scholar 

Arvedson T, Kelly OJ, Yang B. Design rationale and development approach for pegfilgrastim as a long-acting granulocyte colony-stimulating factor. BioDrugs. 2015;29(3):185–98. https://doi.org/10.1007/s40259-015-0127-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kido BYAA. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011;5(50):295–306.

Google Scholar 

Shi YK, Liu P, Yang S, Han XH, He XH, Ai B, et al. phase i clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor. Ai Zheng. 2006;25(4):495–500.

PubMed  Google Scholar 

Yukawa K, Mokuda S, Yoshida Y, Hirata S, Sugiyama E. Large-vessel vasculitis associated with pegylated granulocyte-colony stimulating factor. Neth J Med. 2019;77(6):224–6.

CAS  PubMed  Google Scholar 

Do BH, Kang HJ, Song JA, Nguyen MT, Park S, Yoo J, et al. Granulocyte colony-stimulating factor (gcsf) fused with fc domain produced from E. Coli is less effective than polyethylene glycol-conjugated gcsf. Sci Rep. 2017;7(1):6480. https://doi.org/10.1038/s41598-017-06726-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Semerad CL, Liu F, Gregory AD, Stumpf K, Link DC. G-csf is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity. 2002;17(4):413–23. https://doi.org/10.1016/s1074-7613(02)00424-7.

Article  CAS  PubMed  Google Scholar 

Szade A, Szade K, Nowak WN, Bukowska-Strakova K, Muchova L, Gonka M, et al. Cobalt protoporphyrin ix increases endogenous g-csf and mobilizes hsc and granulocytes to the blood. Embo Mol Med. 2019;11(12):e9571. https://doi.org/10.15252/emmm.201809571.

Article  CAS  Google Scholar 

Mehta P, Porter JC, Manson JJ, Isaacs JD, Openshaw P, McInnes IB, et al. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in covid-19-associated hyperinflammation: challenges and opportunities. Lancet Respir Med. 2020;8(8):822–30. https://doi.org/10.1016/S2213-2600(20)30267-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hatfield KJ, Melve GK, Bruserud O. Granulocyte colony-stimulating factor alters the systemic metabolomic profile in healthy donors. Metabolomics. 2017;13(1):2. https://doi.org/10.1007/s11306-016-1139-x.

Article  CAS  PubMed  Google Scholar 

Hermanns HM. Oncostatin M and interleukin-31: cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 2015;26(5):545–58. https://doi.org/10.1016/j.cytogfr.2015.07.006.

Article  CAS  PubMed  Google Scholar 

Bendall LJ, Bradstock KF. G-csf: from granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine Growth Factor Rev. 2014;25(4):355–67. https://doi.org/10.1016/j.cytogfr.2014.07.011.

Article  CAS  PubMed  Google Scholar 

Tvedt T, Melve GK, Tsykunova G, Ahmed AB, Brenner AK, Bruserud O. Immunological heterogeneity of healthy peripheral blood stem cell donors-effects of granulocyte colony-stimulating factor on inflammatory responses. Int J Mol Sci. 2018;19(10):2886. https://doi.org/10.3390/ijms19102886.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bruserud O, Melve GK, Gedde-Dahl T, Tvedt T. Immunological heterogeneity of healthy peripheral blood stem cell donors—preharvesting donor characteristics, additional heterogeneity induced by granulocyte colony-stimulating factor and possible importance for outcome after allotransplantation. Expert Rev Hematol. 2018;11(10):757–9. https://doi.org/10.1080/17474086.2018.1511420.

Article  CAS  PubMed  Google Scholar 

Melve GK, Ersvaer E, Eide GE, Kristoffersen EK, Bruserud O. Peripheral blood stem cell mobilization in healthy donors by granulocyte colony-stimulating factor causes preferential mobilization of lymphocyte subsets. Front Immunol. 2018;9:845. https://doi.org/10.3389/fimmu.2018.00845.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ilhan C, Suyani E, Sucak GT, Pasaoglu OT, Aki SZ, Pasaoglu H. Inflammatory markers, oxidative stress, and antioxidant capacity in healthy allo-hsct donors during hematopoietic stem cell mobilization. J Clin Apher. 2015;30(4):197–203. https://doi.org/10.1002/jca.21361.

Article  PubMed  Google Scholar 

Fidyk W, Mitrus I, Ciomber A, Smagur A, Chwieduk A, Glowala-Kosinska M, et al. Evaluation of proinflammatory and immunosuppressive cytokines in blood and bone marrow of healthy hematopoietic stem cell donors. Cytokine. 2018;102:181–6. https://doi.org/10.1016/j.cyto.2017.09.001.

Article  CAS  PubMed  Google Scholar